154 related articles for article (PubMed ID: 33754223)
21. The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?
Wroński J; Fiedor P
J Clin Pharmacol; 2019 Apr; 59(4):445-462. PubMed ID: 30476367
[TBL] [Abstract][Full Text] [Related]
22. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.
Sieper J; Appel H; Braun J; Rudwaleit M
Arthritis Rheum; 2008 Mar; 58(3):649-56. PubMed ID: 18311819
[No Abstract] [Full Text] [Related]
23. Efficacy of etanercept in ankylosing spondylitis hip lesions.
Wang D; Ma L; Wu D
Joint Bone Spine; 2011 Oct; 78(5):531-2. PubMed ID: 21570332
[No Abstract] [Full Text] [Related]
24. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
Haraoui B; Krelenbaum M
Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
[TBL] [Abstract][Full Text] [Related]
25. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
[TBL] [Abstract][Full Text] [Related]
26. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
27. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
[TBL] [Abstract][Full Text] [Related]
28. TNF antagonists for ankylosing spondylitis.
Drug Ther Bull; 2005 Mar; 43(3):19-22. PubMed ID: 15762384
[TBL] [Abstract][Full Text] [Related]
29. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
30. Correspondence on 'Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence'.
Zhang ZL; Huang W; Lv GH; Li J; Zou MX; Dai ZH
Ann Rheum Dis; 2022 Dec; 81(12):e252. PubMed ID: 33004326
[No Abstract] [Full Text] [Related]
31. Continuous Improvement of Physical Functioning in Ankylosing Spondylitis Patients by Tumor Necrosis Factor Inhibitors: Three-Year Followup and Predictors.
van Weely SF; Kneepkens EL; Nurmohamed MT; Dekker J; van der Horst-Bruinsma IE
Arthritis Care Res (Hoboken); 2016 Oct; 68(10):1522-9. PubMed ID: 26881893
[TBL] [Abstract][Full Text] [Related]
32. Response to 'Correspondence on "Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence" by Zhang
Koo BS; Oh JS; Park SY; Shin JH; Ahn GY; Lee S; Joo KB; Kim TH
Ann Rheum Dis; 2022 Dec; 81(12):e253. PubMed ID: 33004327
[No Abstract] [Full Text] [Related]
33. Impact of genetic predisposition of de novo uveitis with etanercept in ankylosing spondylitis.
Killian M; Touraine R; Amouzougan A; Thomas T; Marotte H
Ann Rheum Dis; 2015 Mar; 74(3):e22. PubMed ID: 25467296
[No Abstract] [Full Text] [Related]
34. Correction to: Rebuttal letter on "Comment on tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature".
Rocha FAC; Deodhar A
Clin Rheumatol; 2021 Jul; 40(7):3025. PubMed ID: 33948769
[No Abstract] [Full Text] [Related]
35. Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial.
Yates M; Hamilton LE; Elender F; Dean L; Doll H; MacGregor AJ; Thomas J; Gaffney K
J Rheumatol; 2015 Jul; 42(7):1177-85. PubMed ID: 26034151
[TBL] [Abstract][Full Text] [Related]
36. Complete Remission of Nephrotic Syndrome Without Resolution of Amyloid Deposit After Anti-Tumor Necrosis Factor α Therapy in a Patient With Ankylosing Spondylitis.
Lee YH; Kim EY; Jeong DW; Kim YG; Lee SH; Song R; Yang HI; Lim SJ; Moon JY; Lee SH
J Clin Rheumatol; 2016 Mar; 22(2):86-8. PubMed ID: 26906302
[TBL] [Abstract][Full Text] [Related]
37. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis.
van Sijl AM; van Eijk IC; Peters MJ; Serné EH; van der Horst-Bruinsma IE; Smulders YM; Nurmohamed MT
Ann Rheum Dis; 2015 Jan; 74(1):119-23. PubMed ID: 24092419
[TBL] [Abstract][Full Text] [Related]
38. Rapid remission of treatment-resistant ankylosing spondylitis with etanercept--a drug for refractory ankylosing spondylitis?
Barthel HR
Arthritis Rheum; 2001 Aug; 45(4):404. PubMed ID: 11501730
[No Abstract] [Full Text] [Related]
39. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
[TBL] [Abstract][Full Text] [Related]
40. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials.
Baraliakos X; Koenig AS; Jones H; Szumski A; Collier D; Bananis E
J Rheumatol; 2015 Aug; 42(8):1418-26. PubMed ID: 26077401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
